Cragg David
Known title: Chief HR & Admin OfficerCIK: 0001316459
Associated companies
Transaction History
| CYTK | ▼ Sell | Tax Withholding | 5,399 | $199K | 3/7/2022 | View on chart |
| CYTK | ▼ Sell | Tax Withholding | 3,458 | $130K | 3/2/2022 | View on chart |
| CYTK | ▲ Buy | Grant | 20,000 | $0 | 3/2/2022 | View on chart |
| CYTK | ▼ Sell | Tax Withholding | 2,071 | $73K | 2/28/2022 | View on chart |
| CYTK | ▲ Buy | Grant | 1,883 | $0 | 2/16/2022 | View on chart |
| CYTK | ▲ Buy | Grant | 3,125 | $0 | 2/16/2022 | View on chart |
| CYTK | ▲ Buy | Option Exercise | 24,519 | $237K | 11/9/2021 | View on chart |
| CYTK | ▼ Sell | Open Market | 24,519 | $1.0M | 11/9/2021 | View on chart |
| CYTK | ▲ Buy | Option Exercise | 20,481 | $198K | 11/9/2021 | View on chart |
| CYTK | ▼ Sell | Open Market | 20,481 | $855K | 11/9/2021 | View on chart |
| CYTK | ▲ Buy | Option Exercise | 6,675 | $40K | 11/1/2021 | View on chart |
| CYTK | ▼ Sell | Open Market | 6,675 | $233K | 11/1/2021 | View on chart |
| CYTK | ▲ Buy | Option Exercise | 18,325 | $110K | 11/1/2021 | View on chart |
| CYTK | ▼ Sell | Open Market | 18,325 | $639K | 11/1/2021 | View on chart |
| CYTK | ▼ Sell | Open Market | 7,569 | $266K | 10/1/2021 | View on chart |
| CYTK | ▼ Sell | Open Market | 7,850 | $257K | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Cytokinetics Launches ASPEN-HCM Real-World Study
Cytokinetics has initiated the ASPEN-HCM study to evaluate MYQORZO in real-world patients with symptomatic obstructive hypertrophic cardiomyopathy. The company also announced four upcoming presentations at the HFSA Annual Scientific Meeting 2026. These clinical updates provide new data points for investors, while the stock currently trades near its 52-week low.
Cytokinetics Launches ASPEN-HCM Real-World Study. Cytokinetics has initiated the ASPEN-HCM study to evaluate MYQORZO in real-world patients with symptomatic obstructive hypertrophic cardiomyopathy. The company also announced four upcoming presentations at the HFSA Annual Scientific Meeting 2026. These clinical updates provide new data points for investors, while the stock currently trades near its 52-week low.